Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

RAS-mutated mCRC– In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulti...

Related Keywords

San Diego ,California ,United States ,American ,James Levine ,Kiki Patel ,Mark Erlander ,Nasdaq ,American Association For Cancer Research ,Online Program ,Gilmartin Group ,Taft Communications ,Cardiff Oncology Inc ,American Association ,Cancer Research ,Chief Executive Officer ,Bev Revealed ,New Role ,Hypoxia Pathway ,Metastatic Colorectal ,Open Label Study ,Versus Soc Alone ,First Line Treatment ,Metastatic Colorectal Cancer Patient Derived ,Small Cell Lung Cancer ,Cardiff Oncology ,Oncology Contact ,